Risperdal Male Breast-Growth Suit Goes to St. Louis Court

Johnson & Johnson and its unit Janssen Pharmaceuticals Inc. must face a Risperdal male breast-growth suit in a Missouri court that has a plaintiff-friendly reputation.

The U.S. District Court for the Eastern District of Missouri granted a request by 87 plaintiffs to send the case back to the Missouri Circuit Court for the City of St. Louis.

The federal court rejected the drugmakers’ argument that it could easily determine that Missouri courts lacked jurisdiction over non-resident claims, under the U.S. Supreme Court’s decision in Bristol-Myers Squibb Co. v. Superior Court. That ruling limited where corporations could be sued by requiring ...